EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status

Qiong Wu iD, Anders E Berglund iD, Robert J Macaulay, Arnold B Etame iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242015179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Qiong Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, Moffitt Cancer Center Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ) is an important first-line treatment for glioblastoma (GBM), but there are limitations to TMZ response in terms of durability and dependence on the promoter methylation status of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT). MGMT-promoter-hypermethylated (MGMT-M) GBMs are more sensitive to TMZ than MGMT-promoter-hypomethylated (MGMT-UM) GBMs. Moreover, TMZ resistance is inevitable even in TMZ-sensitive MGMT-M GBMs. Hence, epigenetic reprogramming strategies are desperately needed in order to enhance TMZ response in both MGMT-M and MGMT-UM GBMs. In this study, we present novel evidence that the epigenetic reactivation of Tumor Suppressor Candidate 3 (TUSC3) can reprogram sensitivity of GBM stem cells (GSCs) to TMZ irrespective of MGMT promoter methylation status. Interrogation of TCGA patient GBM datasets confirmed TUSC3 promoter regulation of TUSC3 expression and also revealed a strong positive correlation between TUSC3 expression and GBM patient survival. Using a combination of loss-of-function, gain-of-function and rescue studies, we demonstrate that TUSC3 reactivation is associated with enhanced TMZ response in both MGMT-M and MGMT-UM GSCs. Further, we provide novel evidence that the demethylating agent 5-Azacitidine (5-Aza) reactivates TUSC3 expression in MGMT-M GSCs, whereas the combination of 5-Aza and MGMT inhibitor Lomeguatrib is necessary for TUSC3 reactivation in MGMT-UM GSCs. Lastly, we propose a pharmacological epigenetic reactivation strategy involving TUSC3 that leads to significantly prolonged survival in MGMT-M and MGMT-UM orthotopic GSCs models. Collectively, our findings provide a framework and rationale to further explore TUSC3-mediated epigenetic reprogramming strategies that could enhance TMZ sensitivity and outcomes in GBM. Mechanistic and translational evidence gained from such studies could contribute towards optimal design of impactful trials for MGMT-UM GBMs that currently do not have good treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTemozolomideDacarbazineAntineoplastic Agents, AlkylatingDNA MethylationDNA Repair EnzymesDNA Modification MethylasesO(6)-Methylguanine-DNA MethyltransferaseEpigenesis, GeneticCell Line, TumorTumor Suppressor Proteins

Stichwörter der Autor:innen

5-AzaGBMMGMTTMZTUSC3glioma stem cellmethylation

Substanzen

TemozolomideDacarbazineAntineoplastic Agents, AlkylatingDNA Repair EnzymesDNA Modification MethylasesO(6)-Methylguanine-DNA MethyltransferaseMGMT protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
  • Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

ORCID-Profile: Qiong Wu, Anders E Berglund, Arnold B Etame

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • Moffitt Cancer Center Foundation
  • National Cancer Institute
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Wu, Q., Berglund, A. E., Macaulay, R. J., & Etame, A. B. (2023). Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015179

Vancouver

Wu Q, Berglund AE, Macaulay RJ, Etame AB. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015179

BibTeX
@article{Wu2023,
  author = {Wu, Qiong and Berglund, Anders E and Macaulay, Robert J and Etame, Arnold B},
  title = {Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242015179}
}
Kostenlos starten →